Business

LAB/B: Net sales fell 4.9% as FX and weak demand weighed, but LATAM growth and margin gains offset declines

LAB/B: Net sales fell 4.9% as FX and weak demand weighed, but LATAM growth and margin gains offset declines

Genomma Lab Internacional Sab De Cv Class BApril 23, 20265
LAB/B: Net sales fell 4.9% as FX and weak demand weighed, but LATAM growth and margin gains offset declines

About this update from Genomma Lab Internacional Sab De Cv Class B

Net sales declined 4.9% year-over-year due to FX headwinds and weak Mexican consumption, but gross margin expanded and LATAM delivered strong growth. Management expects margin pressure through Q3 as investments defend market share, with recovery in Mexico anticipated later in 2026. Based on This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

View stock analysis, news, and events for Genomma Lab Internacional Sab De Cv Class B

More from Genomma Lab Internacional Sab De Cv Class B

LAB/B: Margins held strong despite sales decline, with recovery and growth initiatives set for 2026

February 26, 2026

LAB/B: Sales declined due to hyperinflation and weak demand, but margins and cost controls remained strong

October 23, 2025

All Genomma Lab Internacional Sab De Cv Class B news →